Intra-Cellular Therapies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ITCI research report →
Companywww.intracellulartherapies.com
Intra-Cellular Therapies, Inc. , a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.
- CEO
- Sharon Mates
- IPO
- 2014
- Employees
- 860
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $14.05B
- P/E
- -182.12
- P/S
- 20.63
- P/B
- 11.84
- EV/EBITDA
- -117.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.63%
- Op Margin
- -17.14%
- Net Margin
- -10.97%
- ROE
- -8.58%
- ROIC
- -10.02%
Growth & Income
- Revenue
- $680.85M · 46.62%
- Net Income
- $-74,676,000 · 46.54%
- EPS
- $-0.72 · 50.68%
- Op Income
- $-116,721,000
- FCF YoY
- 40.95%
Performance & Tape
- 52W High
- $131.98
- 52W Low
- $64.09
- 50D MA
- $129.42
- 200D MA
- $92.67
- Beta
- 0.46
- Avg Volume
- 3.62M
Get TickerSpark's AI analysis on ITCI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 25 | Salas Eduardo Rene | sell | 20,000 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 16,757 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 4,322 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 1,567 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 7,009 |
| Apr 2, 25 | Salas Eduardo Rene | sell | 2,951 |
| Apr 2, 25 | RIGGS RORY B | sell | 7,009 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
| Apr 2, 25 | RIGGS RORY B | sell | 20,000 |
Our ITCI Coverage
We haven't published any research on ITCI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ITCI Report →